From GlobeNewswire:

Mersana Therapeutics, Inc. (NASDAQ: MRSN) is currently enrolling patients in dose escalation and backfill cohorts for phase 1 clinical trials of XMT-1660 and XMT-2056. XMT-1660 is expected to initiate tumor-specific expansion cohorts in Q2 2024, with initial clinical data to be shared in mid-2024. The company is also restarting the Phase 1 clinical trial of XMT-2056 in 2024. Mersana expects these programs to advance the mission of discovering life-changing ADCs for cancer patients.

The company has discussed capital resources, financial resources, collaborations, and upcoming data presentations. It also mentioned webcasting its presentation from the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The President and CEO will share Mersana’s expected 2024 milestones at the conference.

Mersana Therapeutics is a clinical-stage biopharmaceutical company aiming to develop novel ADCs. It has two platforms: Dolasynthen and Immunosynthen. Mersana’s pipeline includes XMT-1660 targeting B7-H4 and XMT-2056 targeting a novel epitope of HER2. Mersana will present its data at the 42nd Annual J.P. Morgan Healthcare Conference. The company plans to make improvements based on customer feedback.

Contact:
For additional inquiries, please contact Jason Fredette via email at [email protected] or at 617-498-0020.



Read more: Mersana Therapeutics Announces Business Updates, Expected